Thrombotic risk in patients with aortic bioprostheses.
Thrombosis of Mosaic aortic valve bioprostheses occurring at more than one month after surgery occurs in 0.8% (95% CI 0.33-1.67%) of patients. In the two cases reported here, each patient had risk factors for thrombus formation, namely severe left ventricular impairment in one patient, while the other patient was heterozygous for prothrombin variant G20210A. The cases were treated successfully, by thrombolytic therapy with streptokinase in the first case, and by repeat aortic valve replacement in the second case. Thrombosis of bioprosthetic valves in the aortic position is rare, and a period of anticoagulation postoperatively does not invariably protect against this serious complication. In conclusion, patients with risk factors for thrombus formation should be considered for long-term anticoagulation.
Edmond
J J
JJ
Cardiology Department, Green Lane Hospital, Green Lane West, Auckland, New Zealand.
Greaves
S C
SC
French
J K
JK
Graham
K J
KJ
Raudkivi
P J
PJ
Blake
J W
JW
Gerber
I L
IL
Smith
W M
WM
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D001021:Aortic Valve / Q000601:surgery*; D001022:Aortic Valve Insufficiency / Q000601:surgery; D001024:Aortic Valve Stenosis / Q000601:surgery; D001705:Bioprosthesis / Q000009:adverse effects*; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006801:Humans; D008297:Male; D011475:Prosthesis Failure; D012086:Reoperation; D012307:Risk Factors; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000209:etiology* / Q000628:therapy*
D000925:Anticoagulants